Merz Therapeutics

Company snapshot

Merz Therapeutics GmbH is dedicated to delivering better outcomes for more patients. With science as its foundation and the patient experience as its focus, the company relentlessly pursues innovative treatments and partnerships to address unmet needs in movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Merz Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Merz Therapeutics.

1. Jun 8, 2026 Clinical update

   NT-PPR-EU002 — Phase 3

2. Jun 8, 2026 Clinical update

   M602011085 — Phase 3

3. Jun 8, 2026 Clinical update

   M602011084 — Phase 3

View all clinical trial activity →

• What is Merz Therapeutics?

  Merz Therapeutics is a pharma organization headquartered in EU. Primary therapeutic focus areas include Moderate to Severe Platysma Prominence, Chronic migraine, Episodic migraine. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entit

• Is Merz Therapeutics publicly traded?

  Merz Therapeutics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Merz Therapeutics develop or market?

  We link 5 drug profile(s) where Merz Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/merz-therapeutics-gmbh#company-drugs.

• What are the latest developments for Merz Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Merz Therapeutics focus on?

  Merz Therapeutics focuses on Moderate to Severe Platysma Prominence, Chronic migraine, Episodic migraine based on our analysis of their pipeline programs and drug development activities.